Premier
Health Signs Agreement with CB2 Insights to Integrate Medical
Cannabis Clinical Decision Support Tool
Data-Driven Technology Firm Begins a First-of-its-Kind Integration
with EMR Platform to Provide Nearly 5,000 Physicians and Healthcare
Practitioners a Tool to Qualify and Prescribe Medical
Cannabis
VANCOUVER, British Columbia, March 27, 2019 -- InvestorsHub
NewsWire -- Premier
Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the
"Company" or "Premier Health"), a Company focused on developing
innovative approaches that combine human skill-based expertise with
emerging technologies for the healthcare industry, is pleased to
announce it has initiated integration of CB2 Insights'
(CBII.CN) medical
cannabis Clinical Decision Support (CDS) tool.
The
agreement will give the more than 4600 physicians and healthcare
practitioners using Premier Health's Juno EMR platform access to
the industry's only medical cannabis-specific CDS
tool.
CB2
Insights' CDS tool is designed to help incorporate medical cannabis
into their patient's treatment plans. This first-of-its-kind
integration in the medical cannabis sector will allow physicians
and healthcare practitioners to overcome many of the barriers they
face from a lack of access to education, qualification factors,
risks and benefits of cannabinoid therapy, all on a
patient-specific basis using clinically-validated data.
"For the
past 4 years, we have continued to work toward simplifying the
process for a physician to gain required understanding amidst the
disparate of clinically validate data sets available when
considering cannabis as an option within a patient's treatment
plan," said Prad
Sekar,
CEO of CB2 Insights. "We are now in a position to benefit from the
aggregated and anonymized data gathered from over 300,000 patient
visits in a clinical environment to power our CDS tool that will
bring clinicians a point-of-care application to help them
incorporate cannabis into their practice and create improved access
for patients who can benefit from cannabinoid therapy."
CB2
Insights, through its clinical arm in the US, operates 28 medical
cannabis evaluation centers staffed with physicians and healthcare
practitioners and creates both access for patients who qualify for
medical cannabis as well as a center of excellence to study and
understand the clinical outcomes of cannabinoid therapy. CB2
gathers data at the point-of-care in a HIPAA-compliant manner, both
aggregated and anonymized, to study trends and outcomes that work
to educate and support stakeholders including but not limited to
physicians and other healthcare professionals.
"We are
dedicated to finding new ways to create value for our physician
network," said Dr. Essam
Hamza, CEO
of Premier Health. "We continue to receive multiple requests from
physicians who ask about how best to incorporate medical cannabis
into their clinics. This agreement with CB2 will provide us a
robust, validated tool to give our physicians and healthcare
practitioners a safe and secure way to qualify, educate and where
appropriate, prescribe medical cannabis to their patients in a
compliant manner."
As part of
the agreement, CB2 will provide the development and continuous
maintenance and support of the CDS tool and all related
technologies. Premier Health will support by providing access to
their software and will engage its network of physicians and other
healthcare professionals to assist in the adoption of the CDS
tool.
ON BEHALF
OF THE BOARD OF DIRECTORS
"Dr.
Essam
Hamza,
MD"
Chief
Executive Officer
Full 3rd
Party Report from StockPrice.com Click Here
About Premier Health
Premier
Health is a Canadian company that is strategically poised to take
advantage of business opportunities in the global health care
industry. We are focused on innovative health care approaches that
combine human skill-based expertise with emerging technologies.
Premier Health, in conjunction with its subsidiary Cloud Practice,
a cloud-based SAAS Electronic Medical Records
software company, is developing proprietary technology to deliver
quality healthcare through the combination of connected primary
care clinics with telemedicine and artificial intelligence (AI). We
currently have a combined ecosystem of 290 clinics, over 3000
licensed practitioners and almost 3 million registered patients.
The Premier Health team has deep clinical, operational and
financial expertise and a passion for improving healthcare for all
patients.
For more
information on Juno EMR, please visit www.junoemr.com.
About CB2 Insights
CB2
Insights has a mission to mainstream medical cannabis into
traditional healthcare.
We do so
by gathering data and creating objective real-world evidence
through our proprietary software and service
brands.
Using
clinical management and data collection software at the
point-of-care, CB2 Insights and its group of sub-brands has become
a leading force behind bringing traditional healthcare protocols to
the rapidly evolving global cannabis industry.
For more
information please visit www.cb2insights.com.
The Canadian Securities Exchange does not accept responsibility for
the adequacy or accuracy of this release.
FOR
ADDITIONAL INFORMATION CONTACT:
Premier
Health Group Inc.
www.mypremierhealth.com
Email:
investors@mypremierhealth.com